Automated Identification and Antimicrobial Susceptibility Testing Solutions
Helping to protect the last line of defense and improved patient outcomes.
We are facing a growing crisis; antimicrobial resistance is eroding our last line of defense against life-threatening infections.
In the U.S., up to 56% of antimicrobial therapies are used inappropriately.1 That’s more than half—driven by overprescription, incorrect dosing, and lack of diagnostic clarity. Not only does inappropriate therapy put the patient at risk, but it also drives resistance. Patients with multidrugresistant infections face 84% higher odds of dying compared to those with treatable infections.2 This isn’t just a statistic—it’s a life-or-death reality for thousands. And the financial impact is staggering. MDR infections can cost hospitals up to $30,000 per patient,3 straining already limited resources and increasing the burden on care teams.
Strengthen your defense with the integrated ID/AST platform made up of the BD Phoenix™ M50, BD Phoenix™ AP and BD Bruker MALDI Biotyper® provides rapid, accurate identification and antimicrobial susceptibility testing for a wide range of pathogens. By standardizing workflows and delivering timely and accurate results, we help clinicians optimize therapy, support antimicrobial stewardship, and fight emerging antimicrobial resistance.
Strengthen your defense against antimicrobial resistance with the ID/AST Solution
Treat with Confidence
BD Phoenix™ M50 delivers highly accurate results and the most complete picture of microbial activity while avoiding downstream workflow inefficiencies.
- Demonstrates ~ 50% lower rate of VMEs (Very Major Errors) for Gram-negative organisms compared to bioMerieux Vitek®4
- True MIC results achieved from dilutions using doubling antibiotic concentrations, and the reading of every well, no extrapolated results
- 136 panel well design accommodates clinically relevant antimicrobials, reducing the need for offline testing
- In an average lab, BD Phoenix™ usage would result in 71% less offline testing annually (compared to bioMerieux Vitek®)5
- Advanced detection algorithms detect what others might miss by actively monitoring for delayed growth patterns
More focus, less fatigue
BD Phoenix™ AP requires fewer repetitive manual tasks to keep your team focused on what matters most:
- Removes repetitive steps
- Automates McFarland preparation reducing hands-on time by 12% compared to bioMerieux Vitek®6
When every minute counts
BD Bruker MALDI Biotyper® provides both rapid and accurate identification with efficiency.
- FDA cleared reference library includes 549 microbial species including 236 gram-positives, 269 gram-negatives, and 44 yeasts
- Non-clinically validated library covers more than 3,400 reference strains
- Less than 10 minutes hands-on time
- 15-20 minutes overall identification time
- Accuracy comparable to Nucleic Acid Sequencing
- A true benchtop system
Every well counts and every well contributes to higher accuracy
BD Phoenix™ panels support true MICs and complete breakpoint coverage, ensuring clinicians get the most accurate data from every test:
- 136-well design provides the highest analytical throughput per panel enabling true doubling dilutions and precise MIC determination
- Optimized well layout accommodates all clinically relevant antimicrobials reducing the need for offline testing
- Ensures critical concentrations are included to detect resistance at or near clinical breakpoints
- Layout allows for updates as resistance patterns and guidelines evolve
Protect today’s patients and tomorrow’s populations
Add dynamic intelligence to your diagnostics with BD Synapsys™ informatics connectivity to BD Phoenix™ and advance your antimicrobial stewardship efforts.
Cascading antimicrobial reporting (CAR)*
- Prioritize antibiotics for bug/drug susceptibility
- Strengthen stewardship by tracking resistance trends
Data-driven insights
- Antibiograms, organism and resistance markers
- Enhance stewardship through narrow-spectrum antibiotic usage
*CAR – patent pending
Strengthen your defense
Our Bloodstream Infection Solution is helping microbiology labs to strengthen your defense against antimicrobial resistance.
BD Diagnostic Solutions is Now Waters Advanced Diagnostics
BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life sciences and diagnostics leader driven by innovation and a relentless commitment to our customers.
As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.
Related Products
Choose the BD BACTEC™ system for seamless integration of blood culture within the full bloodstream infection diagnostic pathway.
Meaningful and actionable insights accessible anytime, anywhere with BD Informatics
Bloodstream Infection Solution
BD Clinical and Lab Support
- Magill SS, O’Leary E, Ray SM, et al. Assessment of the Appropriateness of Antimicrobial Use in US Hospitals. JAMA Netw Open. 2021;4(3):e212007. doi:10.1001/jamanetworkopen.2021.2007
- Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, Yao G. The economic burden of antibiotic resistance: A systematic review and meta-analysis. PLoS One. 2023 May 8;18(5):e0285170. doi: 10.1371/journal.pone.0285170. PMID: 37155660; PMCID: PMC10166566.
- Juang P, Lindsey P, Micek ST, Kollef MH. Cost Implication of Inappropriate Empiric Antibiotics in Gram-Negative Infections. Hosp Pharm. 2024 Dec 12:00185787241303035. doi: 10.1177/00185787241303035. Epub ahead of print. PMID: 39677556; PMCID: PMC11635783
- Van Benten, K., Cooper, L., Parvu, V., Gary, D., Kruer, S., & Kodsi, S. (2025, June). Agreement and error rates in antimicrobial susceptibility testing for three commercial, automated systems: A meta-analysis [Poster presentation]. ASM Microbe, Los Angeles, CA. Poster P2056.
- Based on BD ID/AST TCO Model. Example for demonstration purposes of average size US laboratory and average positivity rates. Model backed by data gathered from US hospital laboratories from BD Insights Research Database (Becton, Dickinson and Company, Franklin Lakes, NJ)
- Junkins AD, Arbefeville SS, Howard WJ, Richter SS 2010. Comparison of BD Phoenix™ AP Workflow with Vitek 2. J Clin Microbiol 48:.https://doi.org/10.1128/jcm.00111-10
- BD™ Bruker MALDI Biotyper® CA System User Manual (8603291)
- BD Phoenix™ M50 User Manual
Disclaimer:
This business has been acquired by Waters Corporation (“Waters”). For products referenced on this page, the legal manufacturer remains Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under the regulatory authority of BD. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary waters.com/bdtransaction.